At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
Recombinant human interleukin-7drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 20, 2004·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating Recombinant human interleukin-7 for HIV Infections. Completed, enrolled 25 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2004
Enrollment StartApr 2005
Study CompletionApr 2007
TodayJul 2026
First PostedDec 20, 2004
Enrollment StartApr 1, 2005
Study CompletionApr 1, 2007
TodayJul 2, 2026
Posted 21.5 years ago
Interventions
Recombinant human interleukin-7drug